Jess Moerland (Student)
Year Start:
2019
Degree:
PhD
Ext Mentor:
Karen Liby, PhD
Programs
Works
- The RXR Agonist MSU-42011 Reduces Tumor Burden in a Murine Preclinical NF1-Deficient Model. Cancers (2025-06-09)
- The Triterpenoid CDDO-Methyl Ester Reduces Tumor Burden, Reprograms the Immune Microenvironment, and Protects from Chemotherapy-Induced Toxicity in a Preclinical Mouse Model of Established Lung Cancer. Antioxidants (2024-05-21)
- The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis. Molecules and Cells (2023-03-31)
- The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner. Antioxidants (2023-01-03)
- The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. Scientific Reports (2022-01-07)
- The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. Cancers (2021-10-06)
- Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice. Scientific Reports (2021-01-13)
- Potential therapeutic uses of rexinoids. Advances in Immunopharmacology (2021)
- The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific Reports (2020-12-17)
- Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. npj Breast Cancer (2019-11-01)
Employment
- Postdoctoral fellow, Indiana University Indianapolis (2025)